NuvOx announces Phase Ib trial for Glioblastoma and additional NIH funding

NuvOx Pharma, a privately held biotechnology company based in Tucson, Arizona, announced that on July 14th, it began a Phase Ib clinical trial of its new drug NVX-108 in patients with glioblastoma, a deadly form of brain cancer.

For more: NuvOx announces Phase Ib trial for Glioblastoma and additional NIH funding